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Summary Seventeen patients with terminal malignancy have been entered into a sequential investigation of two doses of continuous infusion recombinant interleukin-2 (bioleukin) given in the setting of a general ward. After an initial experience of a dose of 300 ug m-2 in eight patients the remainder received 400 gg m-2. Temporary interruption of treatment at the first sign of any serious toxicity led to rapid resolution of sideeffects. No patient needed intensive care support, although nine of 17 required temporary interruption of infusion, lasting on average 4 h. Median lymphocyte rebound on day 14 was 3.6 times the pre-treatment level. It remained above pre-treatment levels in four of five patients who had not shown disease progression at day 56 after more than 28 days off treatment. Minor responses occurred in five patients, lasting on average 4 months.
Over the past 3 years it has become increasingly evident that interleukin-2 (rIL-2) when given in combination with lymphokine activated killer (LAK) cells can produce complete remission in approximately 10% of patients with metastatic renal cell carcinoma or malignant melanoma (Rosenberg et al., 1985 . This was at the price of considerable toxicity, often needing intensive care unit support, although West et al. (1987) suggested that if rIL-2 was given by continuous infusion. ICU support was required less frequently.
Recently, review of the cumulative data from unrandomised trails suggests that there is little evidence to establish the superiority of the combination of rIL-2 and LAK over rIL-2 alone in terms of overall response (Louie et al., 1989) , despite initial analysis of the only randomised trial suggesting that the incidence of durable complete remission in patients receiving combined treatment may be significantly higher (Rosenberg, 1989) . Recent reports have suggested that if the total number of days of rIL-2 treatment is increased from 10 to 20 and the rIL-2 given by continuous infusion in 5-day pulses, the initial response rate may be as good as that reported for combined IL-2/LAK (Paciucci et al., 1988) . However, as yet the incidence of long-term durable CRs has not yet been reported.
Although preclinical and preliminary clinical testing have been reported on at least four different recombinant IL-2 preparations (Thurman et al., 1986) , the majority of literature reports refer to clinical data using the Cetus product. The amino acid sequence of this material differs from natural IL-2 by a single amino acid substitution (cysteine at position 125 has been replaced by serine), and there is an additional mathionine residue at the N-terminal end.
Recently early clinical results have been reported using short-term infusions of bioleukin (Marolda et al., 1987; Gambacorti-Passerini, 1988; Kern et al., 1985) . This preparation of rIL-2 preserves the native amino acid sequence, but does have the additional methionine at the N-terminal end. In the previously mentioned blinded preclinical screen (Thurman et al., 1986) 
Patients and methods
Patients with terminal testicular, renal and prostate cancer and malignant melanoma who had failed prior conventional treatment were treated with IL-2 after giving written informed consent. All had symptoms from tumour metastases and most had WHO performance status 2 or 3. All had at least 3 weeks from completion of previous thereapy and most of the patients with testicular tumour had a life expectancy of less than 3 months.
Dosage
The starting dose was 300ygm-2 (1.7-3.2 x 106 mCi mg' specific activity). The first two patients received 3-day infusions and all subsequent patients received 5-day infusions. The dosage was escalated to 400 Lg m-2 after the first eight patients. This latter group of nine patients, after two 5-day periods of continuous infusion treatment in 14 days, went on to receive 2 weeks of outpatient treatment at a dose of 300 ig m-2 given over 2 h, three times per week.
Patient monitoring All patients had hourly temperature, pulse and blood pressure measurements and were weighed and had routine haematology, renal and liver function performed daily. No pressor drugs or volume expanding treatments were given, and it was planned that hypotension (BP < 80/60), severe (WHO grades 3 and 4) toxicity for any organ system or patient distress would be considered as justification for temporary suspension of infusion. Table I summarises the tumour type, previous history, age and treatment details of the individual patients. The initial patients received shorter duration treatment and lower dosage as part of familiarisation with the effect of treatment. Apart from the first two patients who electively received 3-day cycles, there were three other patients who did not receive two 5-day cycles of treatment because of the rapidity of tumour progression. The remaining 12 patients received two 5-day cycles in 14 days, and seven went on to receive the final 2 weeks of outpatient treatment. (1987) and Thompson et al. (1988) , although their report showed levels slightly higher than those reported in this paper. Although precise equivalence of unitage is difficult to establish, on the basis of specific acitivity determined in our laboratory the upper dose in this study (400 jtg m-2 ) does approximate to that of 5 x 106 Cetus units m-2 which was the upper limit of West et al. (1987) . The equivalence of lymphocyte rebound would support this contention.
Results

Preliminary dosing experience
As yet there is no uniform agreement about which parameter of immune response gives the best correlation with chance of response to treatment. Some authors have noted a correlation with level of in vivo LAK activation (Paciucci et al., 1988) while others have shown a correlation with lymphocytosis (West et al., 1987) . The relative ease of documenting lymphocyte response has obvious advantages and more information is required comparing its discriminatory power with in vivo LAK activation.
Currently, controversy exists as to whether bolus or continuous infusion provides the best method of delivery of rIL-2. The acute toxic effects of a high dose bolus every 8 h are more pronounced, although higher daily doses can be given by bolus injections. At the end of 5 days it is unlikely that there is much difference in the cumulative toxicity although there is some evidence from one author (Kohler et al., 1987) that the level of rebound is higher in patients receiving continuous i.v. infusion compared to i.v. bolus. In addition, at least one study in experimental animals has suggested that the therapeutic effect of interleukin-2 is more closely correlated with the area under the curve than the actual peak level obtained (Cheever et al., 1985) . However, more substantial clinical data are required, as currently only for the intermittent bolus regimen is there evidence that patients have sustained durable complete remissions beyond 2 years (Rosenberg et al., , 1989 .
Most patients in this study showed some toxicity and in nine of 17 this led to temporary interruption of treatment. None had irreversible toxicity and all showed improvement within 30-45 min of stopping treatment. The paradox reported in Table V , although possibly only a reflection of the small number of patients studied to date, is a factor noted from other studies, i.e. that different patients get a different predominant side-effect and that there is not necessarily a correlation between intensity of one side-effect and another. In this study intensity of nausea and liver enyzme changes seemed to be correlated. This may have led to earlier treatment interruption than rising urea becuase it caused greater physical distress to the patients.
A further issue is how far toxicity should temper dosage modification. In the bolus studies the aim has been to sustain the dosage as long as toxicity was not life-threatening (Rosenberg et al., 1985 , while in the patients reported in this paper dosage has been temporarily interrupted at the earliest sign of patient intolerance. As the authors of the bolus regimen have published data showing that steroids may abrogate the beneficial effects of IL-2 (Vetto et al., 1987) it is possible that there could be advantages in not stressing patients to the limits of tolerance, particularly in view of reports from animal studies (Talmadge et al., 1987) and the cumulative data from use of interferon in patients with renal cell carcinoma (Kirkwood et al., 1984) suggesting that there may be a bell shaped dose-response curve for some immunologically based treatments. The early indications of response in the series of patients reported in this paper, and the observation of one partial and one mixed response in the first four patients in our subsequent ongoing phase 2 study, suggest that further investigations of this less aggressive approach is justified.
